We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to ...

Gilead Sciences Inc. closed 8.11% short of its 52-week high of $119.96, which the company achieved on March 10th.

Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $90 ...

Shares of Gilead Sciences (NASDAQ: NASDAQ:GILD) fell 3.4% following a recent Wall Street Journal report indicating that the ...

NORTHAMPTON, MA / ACCESS Newswire / March 18, 2025 / We're proud to once again be ranked in the top five of Americas Most Just companies in biopharma. The honor reflects our ongoing commitment to ...

The Health and Human Services Department is weighing plans to “drastically” cut the federal government’s funding for domestic HIV prevention, ...

The HIV Drugs Market is expected to grow steadily from 2025 to 2035, driven by advancements in antiretroviral therapy and increasing global awareness initiatives. Rising HIV prevalence, improved ...

AstraZeneca has agreed to acquire Belgian in vivo cell therapy biotech EsoBiotec, strengthening its position in the emerging ...

Pharmaceutical companies are currently granted at least eight years’ “protection” over their data from research and clinical ...

Yearly lenacapavir injection for HIV prevention shows safety and long-lasting effects, according to clinical trial results.

In a report released today, Brian Abrahams from RBC Capital initiated coverage with a Buy rating on MoonLake Immunotherapeutics (MLTX – ...